Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650169 · ClinicalTrials.gov registry record · Phase 1
Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00650169: Completed Phase 1 study, sponsored by Mylan Pharmaceuticals.
NCT00650169 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 47 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00650169, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fed conditions.
Interventions
- DRUG Clopidogrel Bisulfate Tablets 75 mg
- DRUG Plavix® Tablets 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-01 |
| Phase | Phase 1 |
What the finished NCT00650169 record still lists
NCT00650169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel Bisulfate Tablets 75 mg is the first listed.
NCT00650169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00650169 about?
NCT00650169 is a clinical study titled "Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg". The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fed conditions.
What is the current status of trial NCT00650169?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2004-12. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00650169?
The interventions under investigation include: Clopidogrel Bisulfate Tablets 75 mg (DRUG), Plavix® Tablets 75 mg (DRUG).
Who is sponsoring clinical trial NCT00650169?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00650169's enrollment target sits among peer trials
47 1053rd of 2000 higher than 943 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia